Search results for Cinpanemab

Cinpanemab Biosimilar – Anti-SNCA mAb – Research Grade, ProteoGenix, PX-TA1573

Description of Cinpanemab Biosimilar - Anti-SNCA mAb - Research Grade Introduction Cinpanemab Biosimilar, also known as Anti-SNCA mAb, is a novel monoclonal antibody that has shown promising results in the treatment of various neurodegenerative diseases. This biosimilar is a research grade version of the original Cinpanemab, which is currently undergoing clinical trials for its therapeutic potential. In this article, we will delve into the structure, activity, and application of Cinpanemab Biosimilar as an antibody targeting SNCA, a key therapeutic target in neurodegenerative disorders. Structure of Cinpanemab Biosimilar Cinpanemab Biosimilar is a monoclonal antibody, meaning it is produced by a single clone of immune cells. It is a humanized IgG1 antibody, which means it has been engineered to have a human-like structure to reduce the risk of immune reactions. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH), while the light chains have two constant regions (CL) and one variable region (VL). The variable regions of the antibody are responsible for binding to the target molecule, SNCA. Activity of Cinpanemab Biosimilar The main activity of Cinpanemab Biosimilar is to bind to and neutralize SNCA, a protein that plays a crucial role in the pathogenesis of neurodegenerative diseases such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. SNCA is a key component of Lewy bodies, abnormal protein aggregates that are found in the brains of patients with these disorders. These aggregates are thought to contribute to neuronal dysfunction and cell death. Cinpanemab Biosimilar specifically targets the N-terminal region of SNCA, which is known to be involved in the aggregation and toxicity of the protein. By binding to this region, the antibody prevents SNCA from forming aggregates and reduces its toxicity, thereby potentially slowing down the progression of neurodegeneration. Application of Cinpanemab Biosimilar Cinpanemab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for its potential as a therapeutic agent for neurodegenerative diseases. The primary application of this antibody is in the treatment of Parkinson’s disease, a progressive disorder characterized by the loss of dopaminergic neurons in the brain. By targeting SNCA, Cinpanemab Biosimilar has the potential to slow down the progression of the disease and improve motor symptoms. In addition to Parkinson’s disease, Cinpanemab Biosimilar may also have applications in other neurodegenerative disorders such as dementia with Lewy bodies and multiple system atrophy. These disorders share similar pathological features with Parkinson’s disease and are also characterized by the presence of Lewy bodies. Conclusion In summary, Cinpanemab Biosimilar is a research grade monoclonal antibody that targets SNCA, a key therapeutic target in neurodegenerative diseases. Its structure, activity, and potential applications make it a promising candidate for the treatment of Parkinson’s disease and other related disorders. Further research and clinical trials will shed more light on the efficacy and safety of this antibody, and it may become a valuable addition to the current treatment options for neurodegenerative diseases.

Cinpanemab, Abbexa, abx831532

Cinpanemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SNCA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Cinpanemab ELISA Kit, ProteoGenix, KPTX227

Description of Cinpanemab ELISA Kit Introduction Cinpanemab is a monoclonal antibody that has been developed as a therapeutic agent for the treatment of various inflammatory diseases. The use of Cinpanemab is based on its ability to specifically target and neutralize a key cytokine involved in the inflammatory response. To facilitate research and development of this antibody, a Cinpanemab ELISA Kit has been developed. In this article, we will provide a detailed description of the structure, activity, and application of the Cinpanemab ELISA Kit. Structure of Cinpanemab ELISA Kit The Cinpanemab ELISA Kit is composed of several components that work together to detect and quantify the presence of Cinpanemab in a sample. The kit includes a microplate coated with a specific antigen that is recognized by Cinpanemab. The microplate also contains wells for the addition of the sample and control solutions. The kit also includes a Cinpanemab-specific enzyme-conjugated secondary antibody, a substrate solution, and a stop solution. Working Principle The working principle of the Cinpanemab ELISA Kit is based on the principle of enzyme-linked immunosorbent assay (ELISA). The microplate is coated with the specific antigen that binds to Cinpanemab. When a sample containing Cinpanemab is added to the microplate, it binds to the antigen. The addition of the Cinpanemab-specific enzyme-conjugated secondary antibody results in the formation of a complex. This complex is then detected by adding the substrate solution, which produces a color change. The intensity of the color is directly proportional to the amount of Cinpanemab present in the sample. The reaction is stopped by adding the stop solution, and the absorbance of the solution is measured using a spectrophotometer. Activity of Cinpanemab ELISA Kit The Cinpanemab ELISA Kit has a high sensitivity and specificity for detecting Cinpanemab in a sample. It has a detection limit of 0.1 ng/mL and a linear range of 0.5-10 ng/mL. The kit also has a low cross-reactivity with other antibodies, ensuring accurate and reliable results. The assay can be completed in less than 3 hours, making it a quick and efficient method for Cinpanemab detection. Validation and Quality Control The Cinpanemab ELISA Kit has undergone extensive validation and quality control to ensure its accuracy and reproducibility. The kit has been tested with various sample types, including serum, plasma, and cell culture supernatants, and has shown consistent results. The kit also includes a set of standard solutions for calibration and a control solution to monitor the assay performance. This ensures the reliability of the results obtained using the kit. Application of Cinpanemab ELISA Kit The Cinpanemab ELISA Kit has a wide range of applications in both research and clinical settings. It can be used to measure the levels of Cinpanemab in biological samples, such as serum and plasma, to monitor the pharmacokinetics of the antibody. The kit can also be used to evaluate the efficacy of Cinpanemab in patients undergoing treatment for inflammatory diseases. In addition, the Cinpanemab ELISA Kit can be used to screen potential therapeutic candidates that target the same antigen as Cinpanemab. Benefits of Using Cinpanemab ELISA Kit The use of the Cinpanemab ELISA Kit offers several benefits compared to other methods of Cinpanemab detection. The ELISA method is highly sensitive and specific, allowing for accurate and precise quantification of Cinpanemab. It is also a cost-effective and time-efficient method, making it a preferred choice for screening and monitoring studies. The kit is also user-friendly and does not require specialized equipment, making it accessible to a wide range of researchers and clinicians.

Cinpanemab ELISA Kit, Abbexa, abx395116

Cinpanemab ELISA Kit is a quantitative ELISA kit for detection of Cinpanemab.Cinpanemab is a human-derived monoclonal antibody directed against α-synuclein. Genetic and pathology evidence implicate this protein in the molecular pathogenesis of Parkinson's disease (PD) and other α-synucleinopathies such as dementia with Lewy bodies (DLB). In 2010, Biogen licensed cinpanemab from Neurimmune. The antibody was generated with reverse translational medicine technology from naturally occurring, presumably protective antibodies found in healthy aged donors, as were aducanumab and other antibodies in the Biogen-Neurimmune partnership. The antibody, previously known as BIIB054, binds to α-synuclein residues 1-10, with 800-fold higher affinity for aggregated over monomeric α-synuclein. The antibody inhibits α-synuclein spreading in cell-based assays, and slows pathology and motor symptoms in mice (Weihofen et al., 2019).

Cinpanemab Biosimilar - Research Grade, ichor.bio, ICH5439

Research Grade Cinpanemab (HW755016), abinScience, HW755016